DHL Supply Chain invests $70m in pharma and healthcare operations

DHL Supply Chain is continuing to invest in its life sciences and healthcare capabilities in North America.

The company has committed more than $70m to develop specialised warehouse facilities and to deploy new pharmaceutical and medical technologies.

This pledge builds on the company’s $150m investment, first announced in June 2019, to expand its US distribution network to bring critical healthcare products closer to trade partners and patients.

Scott Cubbler, president of life sciences and healthcare at DHL Supply Chain North America, explained: “DHL Supply Chain was already well-positioned to support its customers in recent months, thanks to its footprint in North America and the investments it has made in fully licensed sites that meet their storage and handling requirements.

“At the same time, we recognise that demand will only intensify in the future as the market develops its response to the Covid-19 pandemic and adjusts to new ways of addressing patients’ everyday healthcare needs.

“By making this investment, which will also allow us to expand the use of efficiency-boosting new technologies, we are providing our customers with a platform for further growth, as well as the flexibility they need to respond as essential services in a fast-changing environment.”

DHL Supply Chain operates 30 specialised facilities in the US comprising more than 11m sq ft of temperature-controlled infrastructure. More than 9,000 specialists work across DHL’s global network to support the work of pharmaceutical companies, medical devices, clinical trials and research organisations, wholesalers and distributors, as well as hospitals and healthcare providers. 

• DHL GF launches Chitose–Hong Kong charter service to serve scallop market

• AF KLM Cargo and DHL team up on pharma shipment visibility

• DHL Express to open new cargo facility at Munich Airport

• DHL orders three B767 conversions from IAI